Novo Nordisk to Cut Ozempic, Wegovy Prices Up to 50 Percent in US

Global pharmaceutical firm Novo Nordisk on Feb. 24 announced that as of Jan. 1, 2027, it will lower the list price, or wholesale acquisition cost, for its popular weight-loss drugs Ozempic and Wegovy by up to 50 percent.

This will include Wegovy (semaglutide) 2.4 injections and 25 mg tablets, Ozempic (semaglutide) 0.5 mg, 1 mg, and 2 mg injections, and Rybelsus (semaglutide) 7 mg or 14 mg tablets to $675—equating to a reduction of nearly 50 percent for Wegovy and 35 percent of Ozempic from the current list prices.

“Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity, and over 35 million people with Type 2 diabetes in the United States,” Jamey Millar, Novo Nordisk executive vice president of U.S. operations said in the announcement.

“Private and public payers, as well as patients, want access and have been calling for lower list prices. Our actions today answer that call and remove cost barriers so the value of Wegovy and Ozempic can be realized by more patients.”

Millar said that the lower list price will help to connect more people whose out-of-pocket costs are linked to the list price.

According to the drug manufacturer, semaglutide is the active ingredient in both Ozempic and Wegovy, and both are considered  GLP-1s, or glucagon-like peptides. These hormones are produced naturally within the body and regulate blood sugar, as well as suppress appetite and promote fullness. GLP-1s are typically used in the treatment of Type 2 diabetes and obesity.

In addition to GLP-1s, Ozempic and Wegovy contain FDA-approved medicines with indications for adults with Type 2 diabetes, obesity, chronic kidney disease, and co-morbid cardiovascular disease.

“Through this action to lower list prices, Novo Nordisk seeks to improve access to these medicines for even more patients and is the latest in a series of efforts from Novo Nordisk, making it easier and more affordable for people in the U.S. to get authentic, FDA-approved Wegovy and Ozempic in the way that best fits their lives,” the announcement stated.

Novo Nordisk made the money-saving announcement on the heels of its disclosure this week that its newest injectable weight-loss drug, CagriSema, failed to outperform competitor Eli Lilly and Company’s tirzepatide in an 84-week drug trial. Tirzepatide is marketed under the brand names Zepbound and Mounjaro.

As a result of those disappointing and unexpected results, Novo Nordisk experienced a 15 percent drop in its stock prices as of Feb 23.

In November 2025, both Novo Nordisk and Eli Lilly agreed to dramatically reduce the costs of some of their most popular drugs in an agreement brokered by President Donald Trump.

“The agreement represents a historic reduction in prices for Americans on the two drugs with the highest annual expenditures in the United States, both of which help adults struggling with diabetes, heart disease and other conditions,” the announcement said about Novo Nordisk’s Ozempic and Wegovy.

Eli Lilly’s Zepbound and orforglipron were also included in the list of drugs slated for price reductions.

The agreement also stipulates that Eli Lilly and Novo Nordisk will guarantee most-favored-nation (MFN) prices on all new medicines that they bring to market, repatriate increased foreign revenue on existing products, and provide every state Medicaid program in the country access to MFN drug prices on their products.

Based in Denmark, Novo Nordisk has been providing diabetes care for more than a century. The company currently operates in 80 countries and employs more than 68,000 people. Its U.S. headquarters is in Plainsboro, New Jersey, and the pharmaceutical giant operates 10 manufacturing, research and development, and corporate locations in eight states and Washington.